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Abstract
Insulin-like growth factor 1 (IGF-1) has poor anabolic efficacy in
cartilage in osteoarthritis (OA), partly because of its
sequestration by abnormally high levels of extracellular IGF-
binding proteins (IGFBPs). We studied the effect of NBI-31772,
a small molecule that inhibits the binding of IGF-1 to IGFBPs, on
the restoration of proteoglycan synthesis by human OA
chondrocytes. IGFBPs secreted by human OA cartilage or
cultured chondrocytes were analyzed by western ligand blot.
The ability of NBI-31772 to displace IGF-1 from IGFBPs was
measured by radiobinding assay. Anabolic responses in primary
cultured chondrocytes were assessed by measuring the
synthesis of proteoglycans in cetylpyridinium-chloride-
precipitable fractions of cell-associated and secreted 35S-
labeled macromolecules. The penetration of NBI-31772 into
cartilage was measured by its ability to displace 125I-labeled
IGF-1 from cartilage IGFBPs. We found that IGFBP-3 was the
major IGFBP secreted by OA cartilage explants and cultured
chondrocytes. NBI-31772 inhibited the binding of 125I-labeled
IGF-1 to IGFBP-3 at nanomolar concentrations. It antagonized
the inhibitory effect of IGFBP-3 on IGF-1-dependent
proteoglycan synthesis by rabbit chondrocytes. The addition of
NBI-31772 to human OA chondrocytes resulted in the
restoration or potentiation of IGF-1-dependent proteoglycan
synthesis, depending on the IGF-1 concentrations. However,
NBI-31772 did not penetrate into cartilage explants. This study
shows that a new pharmacological approach that uses a small
molecule inhibiting IGF-1/IGFBP interaction could restore or
potentiate proteoglycan synthesis in OA chondrocytes, thereby
opening exciting possibilities for the treatment of OA and,
potentially, of other joint-related diseases.
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Introduction
Insulin-like growth factor 1 (IGF-1) was originally discov-
ered in 1957 by Salmon and Daughaday as a potent
growth-hormone-dependent serum factor able to stimulate
sulfate incorporation by cartilage in vitro [1]. During post-
natal, childhood, and pubertal life, IGF-1 stimulates the lin-
ear growth of bones by increasing the proliferation of
epiphyseal chondrocytes and remodeling processes within
the growth plate cartilage [2,3]. During adulthood, IGF-1
plays a crucial role in the maintenance of homeostasis in
articular cartilage, by stimulating the production of matrix
proteins by chondrocytes [4-6], counteracting their degra-
dation [6-8], and preventing cell death [9,10]. IGF-1 dis-
plays its biological effects in cartilage through the IGF-1
tyrosine kinase receptor [11], structurally related to the het-
erotetrameric insulin receptor [12]. The accessibility of
IGF-1 to its receptor is regulated by extracellular IGF-bind-
ing proteins (IGFBPs), secreted by chondrocytes but also
by the other joint tissues. Although the secretion of IGFBPs
by chondrocytes is constitutive, it is also stimulated by IGF-
1 itself. This mechanism regulates the amount of the free,
bioactive form of IGF-1 [13,14]. In case of need, IGF-1 can
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be released from IGFBPs. The proteolytic cleavage of
IGFBPs by various proteases dramatically decreases their
affinity for IGF-1, thereby increasing its bioavailability [15].
The action of IGF-1 in cartilage is altered during ageing and
in various pathologies such as osteoarthritis (OA), leading
to a decrease of anabolism and a detrimental increase in
catabolic events [16]. Despite the increased degradation
of cartilage in OA, the expression of IGF-1 mRNA is up-reg-
ulated in lesions of OA human cartilage [17-19], and IGF-1
protein levels rise in the synovial fluid of OA patients com-
pared to healthy subjects [20-22]. In dogs, IGF-1 levels in
a knee joint that had undergone cruciate ligament rupture
were fourfold higher than in the contralateral, unaffected
joint [23]. This increased production of IGF-1 in OA
reflected an attempt of cartilage to restore homeostasis,
but it remained inefficacious. IGF-1 receptors were present
and functional in chondrocytes from OA cartilage and thus
were not responsible for the inability of IGF-1 to trigger ana-
bolic events [19,24,25].
IGFBPs are key players in the failure of cartilage to readjust
to homeostasis during OA. Of the six known IGFBPs,
IGFBP-2, -3, and -4 are known to be secreted by articular
cartilage or chondrocytes [25-27], with IGFBP-3 being the
predominant one [28]. The expression of IGFBP-3 was 24
times as high in human OA chondrocytes as in normal
chondrocytes [18], and the amount of IGFBP-3 synthe-
sized by OA cartilage was three times that in normal carti-
lage [29]. Similarly, the amount of IGFBP-3 in OA was
three times that seen in healthy cartilage, and was positively
correlated with the severity of the disease [26]. The molar
concentration of IGFBP-3 in the synovial fluid of OA
patients was higher than that of IGF-1, leading to a molar
ratio of free to bound IGF-1 of less than 1 [21,22]. In such
conditions, no more IGF-1 should be able to reach its
receptors on cartilage. To demonstrate the involvement of
IGFBPs in IGF-1 bioactivity in vitro, Sunic and co-workers
showed that des (1–3) IGF-1, a mutant of IGF-1 lacking the
N-terminal tripeptide and with decreased affinity for
IGFBPs, stimulated the production of proteoglycans by cul-
tured chondrocytes to a higher extent than did IGF-1 [30].
Additionally, anabolic responses of chondrocytes to IGF-1
were dependent on the level of secreted IGFBPs, and the
addition of IGFBP-3 blocked the effects of IGF-1 [31].
According to the growing evidence that IGFBPs (and espe-
cially IGFBP-3) are involved in the decline of the synthesiz-
ing responses of OA cartilage, we hypothesized that these
proteins could be pharmacological targets for the treat-
ment of OA. In this study, a nonpeptide small molecule pre-
viously described as a potent inhibitor of interaction
between IGF and IGFBP [32] was used as a potential tool
to restore the anabolic response of OA chondrocytes to
IGF-1.
Materials and methods
Cells and tissues
Cartilage fragments and chondrocytes were derived from
tibial plateaus and femoral condyles of 3-week-old rabbits
or obtained after surgery for knee replacement in OA
patients (Hôpital Cochin, Paris), as described elsewhere
[33-35]. During the dissection, care was taken to avoid
bony, bloody, or fibrous pieces, and cartilage fragments
were carefully washed before the isolation of chondrocytes.
Rabbit chondrocytes were isolated from cartilage by diges-
tion in Hank's balanced salt solution (HBSS; Invitrogen,
Paisley, UK) containing 3 mg/ml of collagenase (type I;
Worthington, Lakewood, NJ, USA) and 2 mg/ml of dispase
(from Bacillus polymixa; Invitrogen). Human chondrocytes
were isolated from cartilage with similar enzyme concentra-
tions in Ham F12 medium containing 10% fetal calf serum
(FCS). Ethical guidelines for experimental investigations in
animals were followed. The experimental protocols were
used after consultation of the ethics committee of the Insti-
tut de Recherches Servier.
Materials and chemical compounds
Recombinant human IGF-1 (rhIGF-1), R3 rhIGF-1 (an ana-
log of IGF-1 with Arg substituted for Glu at position 3), and
recombinant human IGFBP-3 (rhIGFBP-3) were from
Sigma (St Louis, MO, USA). 125I-labeled IGF-1 and IGF-2
(specific activity 2000 Ci/mmol) were from Amersham Bio-
sciences (Buckinghampshire, UK). NBI-31772 [1-(3,4-
dihydroxybenzoyl)-3-hydroxycarbonyl-6,7-dihydroxyisoqui-
noline; C17H11NO7, 342.06 Da] [32] was synthesized by
Professor J-Y Laronze (University of Reims, Reims, France).
During the course of these experiments, NBI-31772 was
made available from Calbiochem (San Diego, CA, USA).
We use the term 'protease inhibitors' to refer to a commer-
cialized protease inhibitor cocktail (Complete; Roche, Mey-
lan, France) covering a broad spectrum of serine
proteases, cysteine proteases, and metalloproteases.
Radiobinding assay
The ability of NBI-31772 to displace the binding of 125I-
labeled IGF-1 to IGFBP-3 was assessed by radiobinding
assay. Briefly, 125I-labeled IGF-1 (12,000 disintegrations
per minute [dpm]) was incubated in 300 µl of 10 mM phos-
phate-buffered saline (PBS), pH 7.4, containing 0.02%
Nonidet P40 (NP40), with 1 ng IGFBP-3, with or without
various concentrations of IGF-1 or NBI-31772. After 3
hours at room temperature, bound 125I-labeled IGF-1 in the
incubation mixture was separated from free material by pre-
cipitation with 1 ml of 28% polyethylene glycol (PEG 6000)
containing 0.5 mg/ml bovine gamma globulins. After 30
minutes at 4°C, the mixtures were centrifuged for 30 min at
3400 g. Supernatants were removed by aspiration and the
pellets containing 125I-bound IGF-1 were counted in a
gamma counter. The percentage of bound material was
expressed as B/B0 where B represented binding in theAvailable online http://arthritis-research.com/content/6/5/R393
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presence of the competitor and B0 represented binding in
the absence of competitor (maximal binding). Typically, B0
ranged between 25 and 30% and nonspecific binding was
5%. A dose-dependent inhibition was observed with IGF-1,
with a median inhibitory concentration (IC50) of 0.1 nM and
the displacement curve obtained with NBI-31772 was par-
allel to that of IGF-1, with an IC50 of 2 nM.
Western ligand blot analysis of IGFBPs
Chondrocytes were grown in Ham F12 medium containing
10% FCS, 100 IU/ml penicillin, and 100 µg/ml streptomy-
cin. Confluent cells were incubated in serum-free medium
for 24 h. This medium was discarded and cells were further
incubated in fresh, serum-free medium. Explants were dis-
sected out from cartilage, washed extensively with Dul-
becco's phosphate-buffered saline without calcium and
magnesium (DPBS, Gibco), and incubated directly in
serum-free Ham F12 medium without prior incubation in
FCS-containing medium. Secretion media from chondro-
cytes or cartilage explants were collected after 48 hours
and supplemented with protease inhibitors. Samples were
electrophoresed on laboratory-made 7.5–15% gels and
transferred onto a nitrocellulose membrane (Hybond ECL,
Amersham Biosciences) for ligand blot analysis [36]. After
two washes of 5 minutes each in 10 mM Tris-buffered
saline, pH 7.4, containing 0.15 M NaCl (TBS), membranes
were incubated for 30 minutes in TBS containing 3%
NP40 and blocked in TBS containing 0.5% (w/v) gelatin
(Bio-Rad, Hercules, CA, USA) o v e r n i g h t  a t  4 ° C .  M e m -
branes were washed in TBS containing 0.1% Tween-20 for
10 minutes and further dried for 2 hours at room tempera-
ture. Then membranes were incubated in 20 ml of TBS
containing 0.15% gelatin plus a mixture of 125I-labeled IGF-
1 and IGF-2 (5 × 105 dpm of each) for 24 hours at 4°C,
washed twice in TBS containing 0.1% Tween-20, then
three times in TBS, and dried. Gamma radiations corre-
sponding to IGFBPs were captured by autoradiography on
Biomax MS films (Eastman Kodak Co, Rochester, NY,
USA).
Measurement of proteoglycan synthesis by rabbit 
chondrocytes or human OA chondrocytes
Chondrocytes grown to confluence in 24-well plates were
transferred to serum-free medium for 24 hours to discard
FCS components. In type I experiments, designed to com-
pare the effects of IGF-1 and the non-IGFBP binding
mutant of IGF-1, R3 IGF-1, fresh serum-free medium con-
taining 0.1% BSA was added with either peptide and 1.5
µCi/ml Na[35SO4] and incubation was continued for 48
hours. In type II experiments, performed on rabbit chondro-
cytes, fresh, serum-free medium containing 0.1% BSA was
added with or without IGF-1, IGFBP-3, and NBI-31772.
After 2 hours, 1.5 µCi/ml Na[35SO4] was added in each
well and incubation was continued for 24 hours. In type III
experiments, performed on human OA chondrocytes, fresh,
serum-free medium containing 0.1% BSA with or without
IGF-1 or R3 IGF-1 was added to the cells and they were
incubated for 24 hours. Then NBI-31772 was added with-
out renewing the medium, and 1.5 µCi/ml Na[35SO4] was
added 2 hours later. Incubation was continued for 24 more
hours. In both experiment types, the number and DNA con-
tent of cells were not modified by the treatments. The incor-
poration of [35S]sulfate into proteoglycans was determined
in the incubation medium and in the cell layer exactly as
described elsewhere [34]. The cell layer was treated sepa-
rately with 3 M guanidinium chloride in 50 mM Tris/HCl, pH
7.4, for 48 hours at 4°C. Aliquots of the incubation medium
or the cell layer were spotted on Whatman 3 MM paper
(Sigma, St Louis, MO, USA), precipitated with 1% cetylpy-
ridinium chloride containing 0.3 M NaCl, and dried. Scintil-
lation fluid was added and samples were counted in a beta
counter. Statistical differences between treated and con-
trol cells were assessed by Student's t-test.
Binding of 125I-labeled IGF-1 to the surface of cultured 
chondrocytes
Chondrocytes were grown in 12-well dishes in Ham F12
medium containing 10% FCS, 100 IU/ml penicillin, and
100 µg/ml streptomycin. Confluent cells were incubated in
serum-free medium for 6 hours and further incubated for 1
hour at 4°C in 500 µl of DPBS, pH 7.4, containing 0.1%
BSA and protease inhibitors, with 1 × 105 dpm of 125I-
labeled IGF-1 with or without IGF-1 or NBI-31772. Previ-
ous experiments had shown that 125I-labeled IGF-1 bound
specifically to the cell surface of chondrocytes by means of
its receptors. No significant binding to cell-surface IGFBPs
was observed. The incubation medium was harvested and
cells were washed three times with DPBS. Cells were
lysed for 15 minutes in 1 N NaOH. Radioactivities present
in supernatants, lavage media, and cells were counted to
estimate the percentage of cell-associated 125I-labeled
IGF-1.
Competition assay of NBI-31772 with 125I-labeled IGF-1 
binding to cartilage
The methodology was adapted from that of Bhakta and co-
workers [37]. Explants were dissected out from a visually
homogeneous OA cartilage area. Cartilage explants were
minced to less than 1 mm3 and were divided equally and
distributed in a 24-well plate at 20 explants (~2 mg) per
well in 1 ml of DPBS containing 0.1% BSA and protease
inhibitors. NBI-31772, IGF-1, or 1.5 M NaCl was dis-
pensed into wells for 24 hours at 4°C, and 125I-labeled IGF-
1 (20,000 dpm) was added to each well for 24 more hours.
The medium was harvested and distributed into tubes, and
explants were washed three times with 1 ml of DPBS plus
0.1% BSA. Each lavage medium was also collected for
counting. The explants in each well were harvested care-
fully with a spatula and put into tubes, in 1 ml of DPBS,
0.1% BSA. Radioactivity present in medium, lavageArthritis Research & Therapy    Vol 6 No 5    De Ceuninck et al.
R396
medium, and explants was counted. After counting,
explants were harvested, dried for 8 hours at 60°C, and
weighed. The amount of 125I-labeled IGF-1 remaining in
cartilage was corrected for the weight. The percentage dis-
placement was calculated as 100 – [(dpm/mg in explants
in the presence of competitors) / (dpm/mg in explants in
the absence of competitors)] × 100.
Statistics
Data are expressed as means ± SEM. Statistical differ-
ences were analyzed using Student's t-test.
Results
Implication of IGFBPs in the loss of anabolic response in 
OA human chondrocytes
The ability of IGF-1 to stimulate proteoglycan synthesis in
human OA chondrocytes was compared with that of R3
IGF-1, an IGF-1 analog with a greatly reduced affinity for
IGFBPs (Fig. 1). A 48-hour stimulation time with 2.7 nM
IGF-1 was ineffective in promoting proteoglycan synthesis
by chondrocytes. By contrast, 2.7 nM R3 IGF-1 significantly
stimulated total proteoglycan synthesis, by 45% over that
by unstimulated cells. Since IGF-1 and R3 IGF-1 have sim-
ilar affinities for the IGF-1 receptor, the anabolic effect of
IGF peptides depended on the presence of IGFBPs in the
extracellular medium.
Identification of IGFBPs secreted by human OA cartilage 
and chondrocytes
To analyze IGFBPs secreted by chondrocytes, aliquots of
the secretion medium of primary cultured chondrocytes or
cartilage explants were subjected to SDS–PAGE followed
by western ligand blotting (Fig. 2). The identity of secreted
IGFBPs was determined by running rhIGFBP-1, -2, -3, -4, -
5, and -6 in neighbouring wells during electrophoresis. Pri-
mary cultured chondrocytes secreted IGFBP-3 as the
majority IGFBP form (appearing as a characteristic doublet
at 39–42 kDa), and IGFBP-4 was also identified in all spec-
imens consistently, although more faintly. IGFBP-2 was
also found in some specimens. By contrast, IGFBP-3 was
the only IGFBP secreted by OA cartilage explants from var-
ious specimens.
Effect of NBI-31772 on proteoglycan synthesis by rabbit 
articular chondrocytes
Since they respond normally to IGF-1, primary cultured rab-
bit articular chondrocytes were chosen to study the effect
of exogenous IGFBP-3 and NBI-31772 on IGF-1 stimu-
lated proteoglycan synthesis (Fig. 3). IGF-1 (1.3 nM) alone
stimulated total proteoglycan synthesis by a factor of 3.2
(Fig. 3a). The addition of a fourfold molar excess of IGFBP-
3 completely abolished the anabolic effect of IGF-1, and a
slight deleterious effect was even noticed, with proteogly-
can synthesis being 18% less than the control value. Fur-
ther addition of NBI-31772 antagonized the neutralizing
effect of IGFBP-3 on the anabolic effect of IGF-1. NBI-
31772 (1 µM) increased proteoglycan synthesis over that
measured in the presence of IGF-1 plus IGFBP-3 by 28%
(P < 0.05) and this increase reached 210% with 10 µM of
NBI-31772 (P < 0.001), corresponding to 154% over the
basal control value. NBI-31772 by itself had no effect on
Figure 1
Effect of insulin-like growth factor (IGF)-1 and R3 IGF-1 (an analog of  IGF-1 with a greatly reduced affinity for IGF-binding proteins) on total  proteoglycan synthesis by human osteoarthritis chondrocytes Effect of insulin-like growth factor (IGF)-1 and R3 IGF-1 (an analog of 
IGF-1 with a greatly reduced affinity for IGF-binding proteins) on total 
proteoglycan synthesis by human osteoarthritis chondrocytes. Cells 
were stimulated for 48 hours with 2.7 nM IGF-1 or R3 IGF-1 and total 
proteoglycan synthesis was measured. Data are expressed as the 
means and SEM of four replicates from a representative experiment 
(out of three independent cultures). Statistical differences from the con-
trol were measured using Student's t-test. ***P < 0.001.
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Figure 2
Western ligand blotting analysis of insulin-like growth factor (IGF)-bind- ing proteins (IGFBPs) secreted by human osteoarthritis (OA) chondro- cytes or human OA cartilage Western ligand blotting analysis of insulin-like growth factor (IGF)-bind-
ing proteins (IGFBPs) secreted by human osteoarthritis (OA) chondro-
cytes or human OA cartilage. Aliquots of the 48-hour secretion medium 
of confluent OA chondrocytes or cartilage explants were electro-
phoresed and electroblotted onto a nitrocellulose membrane. IGFBPs 
were detected by incubating the membrane with a mixture of 125I-
labeled insulin-like growth factor (IGF)-1 and 125I-labeled IGF-2, fol-
lowed by autoradiography. Shown are two and three representative 
specimens of IGFBP-containing media from chondrocytes and cartilage 
explants, respectively.
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proteoglycan synthesis. NBI-31772 at 10 µM significantly
stimulated the percentage of cell-associated proteogly-
cans in the presence of IGF-1 plus IGFBP-3, with a value
of 40.3% compared to a control value of 31.3% (P  <
0.001) (Fig. 3b). NBI-31772 alone did not significantly
affect the ratio of cell-associated proteoglycans.
Effect of NBI-31772 on proteoglycan synthesis by human 
OA chondrocytes
Depending on the concentration used, IGF-1 has no or little
effect on proteoglycan synthesis by human OA chondro-
cytes, whereas R3 IGF-1 displays higher activity. It there-
fore seems that endogenous IGFBPs are the main
determinants of chondrocyte insensitivity to the action of
IGF-1. To further test this hypothesis, we incubated
chondrocytes for 24 hours with IGF-1 and then added NBI-
31772 to the medium and incubated them for 24 more
hours. We hypothesized that, once captured by IGFBPs
secreted in the extracellular medium, IGF-1 should be
released by addition of the small inhibitor compound and
be able to interact again with its receptor.
IGF-1 at 3.3 nM had no significant anabolic effect (an
increase of 7.8%; not statistically significant) in comparison
with the basal control, but the addition of NBI-31772 at 10
µM stimulated proteoglycan synthesis by 47% over IGF-1
alone (P < 0.001), or 58% over the basal control (Fig. 4a).
A stimulating concentration of IGF-1 (13.3 nM) led to a
52.4% increase in proteoglycan synthesis over the basal
control, and further addition of NBI-31772 at 10 µM
brought this increase to 104.2% (34% more than with IGF-
1 alone; P < 0.001) (Fig. 4b). NBI-31772 alone (added to
cells that did not receive IGF-1) had no effect on proteogly-
can synthesis. These results suggest that NBI-31772
either restored or augmented IGF-1-dependent anabolism
in human OA chondrocytes by disrupting the interaction of
the growth factor with its endogenous IGFBPs. As also
observed in rabbit articular chondrocytes, NBI-31772 at 10
µM stimulated the percentage of cell-associated proteogly-
cans compared with IGF-1 used at 3.3 nM or 13.3 nM, with
values significantly increasing from 13.5% to 15.9% of
total proteoglycans in the former case (P < 0.05), and from
13.0% to 16.0% (P < 0.001) in the latter case (Fig. 4c and
4d).
In further experiments, the stimulating effect of NBI-31772
was tested in the presence of R3 IGF-1 by comparison with
IGF-1. Since R3  IGF-1 does not bind to IGFBPs, we
hypothesized that NBI-31772 should not affect proteogly-
can synthesis induced by this mutant IGF-1. As expected,
NBI-31772 stimulated IGF-1-dependent proteoglycan syn-
thesis in a dose-dependent manner (Fig. 5a), but R3 IGF-1
activity, which by itself was highly enhanced compared with
IGF-1, remained unaffected by NBI-31772 (Fig. 5b). This
experiment definitely ruled out the possibility that NBI-
31772 may act independently of its ability to inhibit the
interaction between IGF-1 and IGFBP. However, the per-
centage of cell-associated proteoglycans was significantly
increased from 13.6% to 16.5% (P < 0.001) when 10 µM
NBI-31772 was added to the medium containing R3 IGF-1
(Fig. 5d), showing that the effect of NBI-31772 on prote-
oglycan redistribution depended on cell responses to IGF-
1 peptides, rather than to their ability to bind to IGFBPs.
NBI-31772 alone did not affect the percentage of cell-
associated proteoglycans (not shown).
Figure 3
Activity of NBI-31772, a small-molecule inhibitor of the binding of insu- lin-like growth factor (IGF)-1 to IGF-binding proteins (IGFBPs), in pri- mary cultured rabbit chondrocytes Activity of NBI-31772, a small-molecule inhibitor of the binding of insu-
lin-like growth factor (IGF)-1 to IGF-binding proteins (IGFBPs), in pri-
mary cultured rabbit chondrocytes. Chondrocytes were incubated for 
24 hours with or without IGF-1, IGFBP-3, or NBI-31772, as indicated, 
in the presence of 1.5 µCi/ml Na[35SO4]. Neosynthesized proteogly-
cans were measured by precipitation of nondialysable macromolecules 
with cetylpyridinium chloride, both in the secretion medium and in the 
cell layer, and by beta-counting. (a) Total proteoglycan synthesis and 
(b) cell-associated proteoglycans, calculated as the ratio of 35S-labeled 
proteoglycans remaining in the cell layer over total proteoglycans. Data 
are expressed as the means and SEM of four replicates from a repre-
sentative experiment (out of five independent cultures). Statistical differ-
ences between groups containing NBI-31772 plus IGF-1 plus IGFBP-
3 and the control group (IGF-1 plus IGFBP-3) were measured by Stu-
dent's t-test. *P < 0.05; ***P < 0.001.
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Effect of NBI-31772 on 125I-labeled IGF-1 binding to 
human OA chondrocytes
To ensure that NBI-31772 did not affect the binding of IGF-
1 to its receptors, it was used as a potential competitor in
a cell-binding assay on human OA chondrocytes (Fig. 6).
125I-labeled IGF-1 bound specifically to confluent chondro-
cytes, since 84% of the radioactivity could be released by
the addition of excess unlabeled IGF-1. When added at the
highest dose used in biological assays (10 µM), NBI-
31772 did not displace specific 125I-labeled IGF-1 binding
from the cell surface.
Competition assay of NBI-31772 with 125I-labeled IGF-1 
for binding to cartilage
This experiment was set up to determine whether NBI-
31772 would displace 125I-labeled IGF-1 from its IGFBPs
within cartilage. To ensure maximal homogeneity, 20
explants coming from a restricted area of a single cartilage
specimen were selected for each well. Cartilage explants
previously incubated with potential competitors or not were
further incubated with 20,000 dpm 125I-labeled IGF-1. The
amount of 125I-labeled IGF-1 remaining in cartilage in the
presence of 11.7 nM IGF-1 was 53% of the control value,
demonstrating that only 47% of the radiolabeled peptide
was bound specifically to proteins within cartilage (Fig. 7).
No further displacement was observed with higher IGF-1
concentrations (not shown). About 43% of the cartilage-
associated radioactivity was removed with 1.5 M NaCl,
showing that nearly half of the 125I-labeled IGF-1 was
bound in a nonspecific manner to cartilage through ionic
interactions, possibly to proteoglycans. By contrast with
IGF-1, R3 IGF-1 did not compete with 125I-labeled IGF-1,
demonstrating that IGF-1 was primarily bound to IGFBPs
within cartilage. NBI-31772 (10 µM) did not compete with
125I-labeled IGF-1 binding to cartilage IGFBPs, suggesting
that it did not penetrate into cartilage.
Discussion
The loss of anabolic responses of chondrocytes to IGF-1 is
one of the reasons why diseased cartilage cannot counter-
act the action of catabolic cytokines during OA. The results
of the present study show that NBI-31772, a small, non-
peptide compound that binds to endogenous IGFBPs and
releases biologically active IGF-1 [32], can restore prote-
oglycan synthesis by human OA chondrocytes, therefore
opening the possibility of a new field of pharmacological
intervention for the treatment of OA and other joint-related
diseases.
As previously demonstrated in ovine and bovine chondro-
cytes [30], a mutant of IGF-1 with strongly decreased affin-
ity for IGFBPs was able to stimulate the synthesis of
Figure 4
Effect of NBI-31772, a small-molecule inhibitor of the binding of insulin-like growth factor (IGF)-1 to IGF-binding proteins (IGFBPs), in primary cul- tured human osteoarthritic chondrocytes incubated with IGF-1 Effect of NBI-31772, a small-molecule inhibitor of the binding of insulin-like growth factor (IGF)-1 to IGF-binding proteins (IGFBPs), in primary cul-
tured human osteoarthritic chondrocytes incubated with IGF-1. Chondrocytes were incubated with (a,c) 3.3 nM or (b,d) 13.3 nM IGF-1 for 24 
hours; NBI-31772 (0.1–10 µM) was added and the cells were incubated for 24 more hours, in the presence of 1.5 µCi/ml Na[35SO4]. (a,b) Total 
proteoglycan synthesis and (c,d) cell-associated proteoglycans calculated by the ratio of 35S-labeled proteoglycans remaining in the cell layer over 
total proteoglycans. Data are expressed as the means and SEM of four replicates from a representative experiment (out of four independent cul-
tures). Statistical differences between groups containing NBI-31772 plus IGF-1 and the respective control group (IGF-1 at 3.3 nM or 13.3 nM) were 
measured by Student's t-test. *P < 0.05; ***P < 0.001.
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proteoglycans by OA chondrocytes to a higher extent than
did IGF-1. This simple but convincing experiment was the
basis for suspecting the involvement of endogenous
IGFBPs in the loss of IGF-1 effects in OA chondrocytes,
and it was a prerequisite to justify their targeting. Three
forms of IGFBPs were found to be secreted by human OA
chondrocytes, the major one being IGFBP-3. OA cartilage
explants secreted IGFBP-3 exclusively. In a functional radi-
obinding assay, NBI-31772 displaced the binding of 125I-
labeled IGF-1 at a molar concentration 20 times that of
unlabeled IGF-1. Although the ability of NBI-31772 to dis-
place  125I-labeled IGF-1 from the other IGFBPs has not
been checked in this study, it has been previously shown
that it can interact with all six IGFBPs with similar efficacy
[32]. Therefore, it is probable that in the experiments with
OA chondrocytes, NBI-31772 also acted by displacing
IGF-1 from IGFBP-2 and -4 in addition to IGFBP-3.
In the first set of experiments with rabbit chondrocytes,
IGFBP-3 at a concentration four times that of IGF-1
completely abolished the stimulation of proteoglycan syn-
thesis by IGF-1, and NBI-31772 partially restored IGF-1-
dependent synthetic activities at 1 µM and almost totally at
10 µM. These concentrations were much higher than those
found to displace 125I-labeled IGF-1 from IGFBP-3 in the
radiobinding assay. This discrepancy was also found in a
previous study reporting the activity of NBI-31772 on the
reversal of IGFBP-3 inhibition of Balb/c3T3 IGF-1-depend-
ent proliferation [38]. The higher amounts of IGFBP-3 used
in the biological assays compared with the radiobinding
assay may in part account for this discrepancy. On the
other hand, differences may rest on a decreased stability of
the chemical compound in a biological environment and/or
to its capture or neutralization by chondrocyte-secreted
proteins or macromolecules, thus limiting its activity. Similar
results were found for human OA chondrocytes, without
a d d i t i o n  o f  I G F B P - 3 .  I n  t h i s  c e l l u l a r  m o d e l ,  w e  a s k e d
whether NBI-31772 could displace IGF-1 from endog-
enous IGFBPs. As also found by others [27,29,39], IGF-1
was either not detectable or poorly detectable in the extra-
cellular medium, reflecting poor ability of chondrocytes to
secrete IGF-1. Thus, it was given exogenously. The addition
of NBI-31772 was able to activate or increase proteogly-
can synthesis, showing that complexes of IGF-1 with
IGFBP could be disrupted to release bioactive IGF-1. NBI-
31772 also significantly increased the ratio of cell-associ-
ated proteoglycans in the presence of IGF-1/IGFBP com-
plexes. When, in these experiments, IGF-1 was replaced by
R3 IGF-1, the stimulating effect of NBI-31772 on proteogly-
can synthesis was completely abolished, thus ruling out the
possibility that NBI-31772 may act independently of the
inhibition of IGF-1-binding to IGFBPs. However, an
Figure 5
Comparative activity of NBI-31772, a small-molecule inhibitor of the binding of insulin-like growth factor (IGF)-1 to IGF-binding proteins (IGFBPs), in  primary cultured human osteoarthritic chondrocytes incubated with IGF-1 or R3 IGF-1 (an analog of IGF-1 with a greatly reduced affinity for IGFBPs) Comparative activity of NBI-31772, a small-molecule inhibitor of the binding of insulin-like growth factor (IGF)-1 to IGF-binding proteins (IGFBPs), in 
primary cultured human osteoarthritic chondrocytes incubated with IGF-1 or R3 IGF-1 (an analog of IGF-1 with a greatly reduced affinity for IGFBPs). 
Chondrocytes were incubated with (a,c) 3.3 nM IGF-1 or (b,d) 3.3 nM R3 IGF-1 for 24 hours; NBI-31772 (0.1–10 µM) was added and the cells 
were incubated for 24 more hours in the presence of 1.5 µCi/ml Na[35SO4]. (a,b) Total proteoglycan synthesis and (c,d) cell-associated proteogly-
cans, calculated from the ratio of 35S-labeled proteoglycans remaining in the cell layer over total proteoglycans. Data are expressed as the means 
and SEM of four replicates from a representative experiment (out of four independent cultures). Statistical differences between groups containing 
NBI-31772 plus IGF-1 or R3 IGF-1 and the respective control groups (IGF-1 or R3 IGF-1) were measured using Student's t-test. *P < 0.05; ***P < 
0.001.
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increase of cell-associated proteoglycans was still
observed, showing that this effect of NBI-31772 occurred
apart from IGFBPs. Although unexplained, this mechanism
may be important in a pathological context, since commu-
nication between chondrocytes and the extracellular matrix
is disrupted in OA, and an increase of pericellular prote-
oglycans may help to maintain chondrocytes in a more favo-
rable environment.
Under physiological conditions, IGF-1/IGFBP complexes
can be disrupted by various proteases [15], thereby
releasing active IGF-1. In a recent report by Fowlkes and
co-workers, matrix metalloproteinase 3 was able to disrupt
IGF/IGFBP-3 complexes and to liberate free, intact IGFs
able to phosphorylate the IGF-1 receptor and to trigger cell
proliferation [40]. A few different approaches have been
used to prevent excessive sequestration of IGF-1 and
restore its bioavailabity in pathological conditions. Mutant
peptides of IGF-1 still able to bind to IGFBPs but with very
weak affinity for the IGF-1 receptor were designed to dis-
place native IGF-1 from endogenous IGFBPs [41-45].
Phage-displayed peptide libraries yielded small peptide
compounds able to selectively displace IGF-1 from IGFBP-
1 or IGFBP-3 [45,46]. From the last generation, low-molec-
ular-weight compounds (fluorenylmethoxycarbonyl deriva-
tives) were shown to bind to the IGF-1 binding site on
IGFBP-5 [47], and small isoquinoline compounds were
shown to displace IGFs from IGFBPs without selectivity for
a particular IGFBP [32,38,44,48,49]. These molecules
have been proposed as potential drug candidates for the
treatment of diabetes [32,45], renal disease [50], or neuro-
degenerative diseases [43,44].
Most of the current pharmacological approaches for the
treatment of OA aim to prevent catabolism by blocking
actors of the deleterious cascade, while restoration of
anabolism or cartilage regeneration still rests on invasive
procedures [51]. In this context, in situ cartilage
Figure 6
Effect of NBI-31772, a small-molecule inhibitor of the binding of insulin- like growth factor (IGF)-1 to IGF-binding proteins, on 125I-labeled IGF-1  binding to human osteoarthritic chondrocytes Effect of NBI-31772, a small-molecule inhibitor of the binding of insulin-
like growth factor (IGF)-1 to IGF-binding proteins, on 125I-labeled IGF-1 
binding to human osteoarthritic chondrocytes. Confluent chondrocytes 
were incubated with 1 × 105 dpm 125I-labeled IGF-1 with or without 
excess (150 nM) IGF-1 or 10 µM NBI-31772 for 1 hour at 4°C. 
Medium was harvested and cells were washed three times with Dul-
becco's phosphate-buffered saline. Cells were lysed in 1 N NaOH. The 
percentage of 125I-labeled IGF-1 bound to the cells was calculated as 
dpm in NaOH-treated cells over total dpm. Data are expressed as the 
means and SEM of four replicates from a representative experiment 
(out of two independent cultures).
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Figure 7
Competition of NBI-31772, a small-molecule inhibitor of the binding of insulin-like growth factor (IGF)-1 to IGF-binding proteins (IGFBPs), with 125I- labeled IGF-1 binding to cartilage Competition of NBI-31772, a small-molecule inhibitor of the binding of insulin-like growth factor (IGF)-1 to IGF-binding proteins (IGFBPs), with 125I-
labeled IGF-1 binding to cartilage. Explants cut from a homogeneous area of osteoarthritic cartilage were separated in equal groups and incubated 
with 11.7 nM R3 IGF-1 (an analog of IGF-1 with a greatly reduced affinity for IGFBPs), 11.7 nM IGF-1, 1.5 M NaCl or 10 µM NBI-31772 in 1 ml of 
Dulbecco's phosphate-buffered saline (DPBS) for 24 hours at 4°C. 125I-labeled IGF-1 (20,000 dpm) was added to each incubation medium and the 
cells were incubated for 24 more hours. The medium was harvested and explants were washed three times with DPBS. The radioactivity in medium, 
lavage buffer, and cartilage explants was counted. The percentage of 125I-labeled IGF-1 remaining in cartilage was corrected for the weight of 
explants and divided by total counts. Data are the means of two experiments. Results are expressed as percentages of the control value (cartilage 
incubated with 125I-labeled IGF-1 alone).
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regeneration by growth-factor therapy, including targeting
of cartilage defects with fibrin–(chondrocyte)–IGF-1 com-
posites [52,53], or gene therapy with IGF-1 delivered intra-
articularly [54-56], have been proposed. To be effective,
the amount of IGF-1 delivered within the joint in this way
should exceed the binding capacity of local IGFBPs. In
addition to noninvasive intervention, one of the main advan-
tages of our proposed strategy would be to target directly
the actors of cartilage unresponsiveness to IGF-1, and to
bypass the capture of exogenous IGF-1 by IGFBPs. Keep-
ing this objective in mind, it is clear that the small com-
pound used in this study, NBI-31772, should be
considered only a tool to demonstrate the concept in vitro.
Indeed, concentrations of NBI-31772 active in the biologi-
cal assays were relatively high (1–10 µM) and would be
incompatible with in vivo trials. Secondly, NBI-31772 did
not penetrate into cartilage. This should not be an exclusion
criterion per se, since one may hypothesize that if the com-
pound were capable of reaching the synovial fluid or carti-
lage surrounding tissues, it might release IGF-1 captured
by IGFBPs in these tissues and sustain its action in carti-
lage. However, the in vivo duration of action of NBI-31772
was short [48], which implies that in vivo trials to assess
the therapeutic relevance of this class of molecule in joint
diseases need to be performed with more stable mole-
cules. In view of a therapeutic application, the optimization
of small chemical inhibitors of IGF/IGFBP interaction would
be preferred over the use of IGF-1 peptide mutants (either
binding receptors and triggering biological effects without
binding IGFBPs, or, conversely, displacing endogenous
IGF-1 from IGFBPs without binding receptors), since the
former should be more easily optimizable while the latter
should be more susceptible to the attack by proteases. In a
clinical context, compounds that selectively target IGFBP-
3 would be mandatory if oral availability is preferred, in
order to avoid or to limit side effects caused by displacing
IGF-1 from its binding proteins in undesirable tissues. This
question of selectivity may not be so important in the case
of topical delivery, and local treatment should be envisaged
instead.
Conclusion
A small, nonpeptide pharmacological inhibitor of IGF/
IGFBP interaction restored or enhanced the IGF-1-
dependent proteoglycan synthesis by human osteoarthritic
chondrocytes. This finding offers a rationale for pharmaco-
logical intervention in the treatment of cartilage repair in
osteoarthritis and potentially of other joint-related diseases
and shows that IGFBPs are pertinent target candidates for
this purpose.
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